V Square Quantitative Management LLC Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

V Square Quantitative Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,319 shares of the company's stock after purchasing an additional 1,778 shares during the quarter. Johnson & Johnson makes up 1.0% of V Square Quantitative Management LLC's investment portfolio, making the stock its 12th biggest holding. V Square Quantitative Management LLC's holdings in Johnson & Johnson were worth $6,843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of JNJ. AMF Tjanstepension AB raised its stake in Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock valued at $68,985,000 after buying an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $209,000. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $213,000. Swedbank AB lifted its stake in Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after purchasing an additional 111,570 shares during the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI boosted its holdings in Johnson & Johnson by 1.8% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company's stock valued at $15,798,000 after purchasing an additional 1,768 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Remove Ads

Johnson & Johnson Trading Up 1.7 %

JNJ stock traded up $2.67 during midday trading on Friday, hitting $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company's 50-day moving average price is $148.93 and its 200 day moving average price is $155.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the firm posted $2.29 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Weinberger bought 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Barclays boosted their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.